Cargando…

The making of multivalent gamma delta TCR anti-CD3 bispecific T cell engagers

INTRODUCTION: We have recently developed a novel T cell engager concept by utilizing γ9δ2TCR as tumor targeting domain, named gamma delta TCR anti-CD3 bispecific molecule (GAB), targeting the phosphoantigen-dependent orchestration of BTN2A1 and BTN3A1 at the surface of cancer cells. GABs are made by...

Descripción completa

Detalles Bibliográficos
Autores principales:	van Diest, Eline, Nicolasen, Mara J. T., Kramer, Lovro, Zheng, Jiali, Hernández-López, Patricia, Beringer, Dennis X., Kuball, Jürgen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9851377/ https://www.ncbi.nlm.nih.gov/pubmed/36685546 http://dx.doi.org/10.3389/fimmu.2022.1052090

Ejemplares similares

Gamma delta TCR anti-CD3 bispecific molecules (GABs) as novel immunotherapeutic compounds
por: van Diest, Eline, et al.
Publicado: (2021)

Characterization and modulation of anti-αβTCR antibodies and their respective binding sites at the βTCR chain to enrich engineered T cells
por: Kierkels, Guido J.J., et al.
Publicado: (2021)

Correction: Gamma delta TCR anti-CD3 bispecific molecules (GABs) as novel immunotherapeutic compounds
Publicado: (2021)

Clinical Applications of Gamma Delta T Cells with Multivalent Immunity
por: Deniger, Drew C., et al.
Publicado: (2014)

Comparing CAR and TCR engineered T cell performance as a function of tumor cell exposure
por: Wachsmann, Tassilo L. A., et al.
Publicado: (2022)

Surface expression of a T cell receptor beta (TCR-beta) chain in the absence of TCR-alpha, -delta, and -gamma proteins
Publicado: (1991)

T cells with gamma/delta T cell receptors (TCR) of intestinal type are preferentially expanded in TCR-alpha-deficient lpr mice
Publicado: (1995)

Multivalent in vivo delivery of DNA-encoded bispecific T cell engagers effectively controls heterogeneous GBM tumors and mitigates immune escape
por: Park, Daniel H., et al.
Publicado: (2023)

Multivalent Engagement of TFIID to Nucleosomes
por: van Nuland, Rick, et al.
Publicado: (2013)

Mammalian Display Platform for the Maturation of Bispecific TCR-Based Molecules
por: Dilchert, Janine, et al.
Publicado: (2022)

TCR-mimic bispecific antibodies to target the HIV-1 reservoir
por: Sengupta, Srona, et al.
Publicado: (2022)

Adding Help to an HLA-A*24:02 Tumor-Reactive γδTCR Increases Tumor Control
por: Johanna, Inez, et al.
Publicado: (2021)

A novel antibody-TCR (AbTCR) platform combines Fab-based antigen recognition with gamma/delta-TCR signaling to facilitate T-cell cytotoxicity with low cytokine release
por: Xu, Yiyang, et al.
Publicado: (2018)

P1463: PHASE I DOSE ESCALATION OF LAVA-051, A NOVEL BISPECIFIC GAMMA-DELTA T-CELL ENGAGER (GAMMABODY™), IN RELAPSED/REFRACTORY HEMATOLOGICAL MALIGNANCIES
por: Broijl, A., et al.
Publicado: (2022)

The making of bispecific antibodies
por: Brinkmann, Ulrich, et al.
Publicado: (2017)

Human TCR-gamma+/delta+, CD8+ T lymphocytes recognize tetanus toxoid in an MHC-restricted fashion
Publicado: (1989)

Increasing functional avidity of TCR-redirected T cells by removing defined N-glycosylation sites in the TCR constant domain
por: Kuball, Jürgen, et al.
Publicado: (2009)

Gamma Delta TCR and the WC1 Co-Receptor Interactions in Response to Leptospira Using Imaging Flow Cytometry and STORM
por: Gillespie, Alexandria, et al.
Publicado: (2021)

The landscape of bispecific T cell engager in cancer treatment
por: Zhou, Shujie, et al.
Publicado: (2021)

Non-V delta 2 gamma delta T lymphocytes as effectors of cancer immunotherapy
por: Fisher, Jonathan, et al.
Publicado: (2014)

A Brain-Targeting Bispecific-Multivalent Antibody Clears Soluble Amyloid-Beta Aggregates in Alzheimer’s Disease Mice
por: Rofo, Fadi, et al.
Publicado: (2022)

Early Pregnancy Human Decidua is Enriched with Activated, Fully Differentiated and Pro-Inflammatory Gamma/Delta T Cells with Diverse TCR Repertoires
por: Terzieva, Antonia, et al.
Publicado: (2019)

The small chain fatty acid butyrate antagonizes the TCR-stimulation-induced metabolic shift in murine epidermal gamma delta T cells
por: Häselbarth, Lukas, et al.
Publicado: (2020)

Immunoregulatory functions for murine intraepithelial lymphocytes: gamma/delta T cell receptor-positive (TCR+) T cells abrogate oral tolerance, while alpha/beta TCR+ T cells provide B cell help
Publicado: (1992)

Mathematical and numerical methods for the nonlinear hyperbolic propagation problem delta$^{2}$GAMMA/delta.t$^{2}$ = (delta/delta.z)((delta.GAMMA(delta.t)(delta.GAMMA/delta.z)): a preliminary treatment of collective space
por: Funk, U N, et al.
Publicado: (1982)

For whom the T cells troll? Bispecific T-cell engagers in glioblastoma
por: Singh, Kirit, et al.
Publicado: (2021)

Differential expression of CD45RO (UCHL1) and its functional relevance in two subpopulations of circulating TCR-gamma/delta+ lymphocytes
Publicado: (1990)

High throughput development of TCR-mimic antibody that targets survivin-2B(80-88)/HLA-A*A24 and its application in a bispecific T-cell engager
por: Kurosawa, Nobuyuki, et al.
Publicado: (2019)

Developmental arrest of NK1.1+ T cell antigen receptor (TCR)- alpha/beta+ T cells and expansion of NK1.1+ TCR-gamma/delta+ T cell development in CD3 zeta-deficient mice
Publicado: (1995)

Therapeutic Bispecific T-Cell Engager Antibody Targeting the Transferrin Receptor
por: Fu, Mingpeng, et al.
Publicado: (2019)

Overcoming leukemia heterogeneity by combining T cell engaging bispecific antibodies
por: Hoseini, Sayed Shahabuddin, et al.
Publicado: (2020)

Bispecific T-Cell Engagers Targeting Membrane-Bound IgE
por: Rodak, Aleksandra, et al.
Publicado: (2021)

Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies
por: Tian, Zheng, et al.
Publicado: (2021)

Dichotomous impact of affinity on the function of T cell engaging bispecific antibodies
por: Poussin, Mathilde, et al.
Publicado: (2021)

Bispecific T Cell Engagers for the Treatment of Multiple Myeloma: Achievements and Challenges
por: Alhallak, Kinan, et al.
Publicado: (2021)

Combination therapies for the optimisation of Bispecific T-cell Engagers in cancer treatment
por: Zhu, Winston M, et al.
Publicado: (2023)

Simultaneous Multiple Interaction T-cell Engaging (SMITE) Bispecific Antibodies Overcome Bispecific T-cell Engager (BiTE) Resistance Via CD28 Co-Stimulation
por: Correnti, Colin E., et al.
Publicado: (2018)

Current experimental status of $ \Delta \Gamma$ and $ \Delta m$
por: Schiller, Manuel Tobias
Publicado: (2018)

A measurement of $\Delta \Gamma_{s}$
por: Aaij, Roel, et al.
Publicado: (2023)

Immunoglobulin Gamma-Like Therapeutic Bispecific Antibody Formats for Tumor Therapy
por: Chen, Shixue, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_70ag6q359c25palekemovdoehv